Katherine Baicker - Eli Lilly Independent Director
| LLY Stock | USD 750.77 0.87 0.12% |
Director
Dr. Katherine Baicker, Ph.D., is an Independent Director of the Company. She is Professor of Health Economics at the Harvard University School of Public Health, Department of Health Policy and Management and Research Associate at the National Bureau of Economic Research Dr. Baicker was a professor of health economics at the Department of Health Policy and Management, School of Public Health, since 2007. From 2005 to 2007, she served as a Senateconfirmed member of the Council of Economic Advisers. From 1998 to 2005, Dr. Baicker was assistant professor and associate professor of economics at Dartmouth College. In 2001 and 2002 she also served as an economist to the Council of Economic Advisers, Executive Office of the President, and in 2003 was a visiting assistant professor at the University of Chicago Harris School of Public Policy since 2011.
| Age | 49 |
| Tenure | 13 years |
| Address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has Return on Asset of 0.1188 % which means that on every $100 spent on assets, it made $0.1188 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4844 %, implying that it generated $0.4844 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joseph Mollica | Neurocrine Biosciences | 59 | |
| Gary Michael | PetIQ Inc | 77 | |
| Will Santana | PetIQ Inc | 45 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Mark First | PetIQ Inc | 53 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Corinne Nevinny | Neurocrine Biosciences | 57 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| James Clarke | PetIQ Inc | 45 | |
| Larry Bird | PetIQ Inc | 63 | |
| Susan Sholtis | PetIQ Inc | 51 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Scott Huff | PetIQ Inc | 46 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
| Ronald Kennedy | PetIQ Inc | 71 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| George Joulwan | Emergent Biosolutions | 80 | |
Management Performance
| Return On Equity | 0.48 | ||||
| Return On Asset | 0.12 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ralph Alvarez, Independent Director | ||
| Jamere Jackson, Independent Director | ||
| Johna Norton, Senior Vice President - Global Quality | ||
| Juan Luciano, Lead Independent Director | ||
| J Fyrwald, Independent Director | ||
| Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
| Anne White, Senior Vice President and Presidentident - Lilly Oncology | ||
| Mark MD, Senior Development | ||
| Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
| Patrik Jonsson, Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA | ||
| Karen Walker, Independent Director | ||
| Ilya Yuffa, Senior Vice President and President of Lilly Bio-Medicines | ||
| Bronwen Mantlo, Deputy VP | ||
| Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA | ||
| Raul Alvarez, Independent Director | ||
| Marschall Runge, Independent Director | ||
| Anat JD, General VP | ||
| Myles ONeill, Senior Vice President and President - Manufacturing Operations | ||
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Daniel Skovronsky, Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories | ||
| Edgardo Hernandez, Senior Vice President and Presidentident - Manufacturing Operations | ||
| Donald Zakrowski, Senior Officer | ||
| Carolyn Bertozzi, Independent Director | ||
| Erik Fyrwald, Independent Director | ||
| David MD, Chief Officer | ||
| Franklyn Prendergast, Independent Director | ||
| Ellen Marram, Lead Independent Director | ||
| Kathi Seifert, Independent Director | ||
| Eric Dozier, Executive Diversity | ||
| Joshua Smiley, Chief Financial Officer, Senior Vice President | ||
| Anat Hakim, Senior Vice President, General Counsel, Secretary | ||
| Fionnuala Walsh, Senior Vice President - Global Quality | ||
| Alonzo Weems, Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer | ||
| Jim Greffet, Head Strategy | ||
| Gabrielle Sulzberger, Independent Director | ||
| Anat Ashkenazi, Chief Financial Officer, Senior Vice President | ||
| Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
| John Lechleiter, Chairman, CEO and Pres | ||
| Karen Horn, Independent Director | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Darren Carroll, Senior Vice President - Corporate Business Development | ||
| William Kaelin, Independent Director | ||
| Jacob Naarden, Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology | ||
| Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines | ||
| Barton Peterson, Senior Vice President - Corporate Affairs and Communications | ||
| Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee | ||
| Kimberly Johnson, Independent Director | ||
| Michael Harrington, Executive Vice President, General Counsel | ||
| David Hoover, Independent Director | ||
| Maria Crowe, President - Manufacturing Operations | ||
| Diogo Rau, Senior Vice President Chief Information and Digital Officer | ||
| Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories | ||
| Aarti Shah, Senior Vice President - Chief Information and Digital Officer | ||
| Susan Mahony, Senior Vice President and President - Lilly Oncology | ||
| Jackson Tai, Independent Director | ||
| Michael Eskew, Independent Director | ||
| Martin MIBS, VP Projects | ||
| Katherine Baicker, Independent Director | ||
| Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
| Michael Mason, Senior Vice President and President Lilly Diabetes | ||
| Winselow Tucker, Senior Loxo |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.48 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 699.33 B | ||||
| Shares Outstanding | 950.77 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 84.31 % | ||||
| Number Of Shares Shorted | 5.42 M | ||||
| Price To Earning | 54.92 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.78 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.